缺血缺氧性血-视网膜屏障损伤机制及药物治疗的研究进展

Current research of hypoxic-ischemic blood-retinal barrier inflammatory breakdown

缺血缺氧性血-视网膜屏障(BRB)损伤是许多眼病和某些全身疾病所共有的病理损害,严重损害患者视力。BRB损伤的发病机制目前尚不明确,近年来有文献报道,炎症反应以及血管内皮生长因子(VEGF)、色素上皮源性生长因子(PEDF)、细胞间黏附因子-1(ICAM-1)、白细胞介素(IL)和肿瘤坏死因子-α(TNF-α)等炎性因子与该病变的发生发展密切相关,应用糖皮质激素、抗VEGF抗体、非甾体类抗炎药(NSAIDs)、褪黑激素抑制炎症反应过程为保护BRB开辟了新的途径。本文就缺血缺氧性BRB炎症损伤机制及利用抑制炎症反应及炎性因子的方法治疗BRB损伤的机制进行综述。

Loss of the hypoxic-ischemic blood-retinal barrier（BRB） is the common pathology of a wide number of retinal diseases and some general diseases, which seriously affects visual acuity. Although the actual mechanism of BRB damage is not yet completely clear, mounting evidence suggests that the development of BRB damage may be associated with inflammatory processes and inflammatory factors, such as vascular endothelial growth factor（VEGF）, pigment epithelium derived growth factor（PEDF）, intercellular adhesion molecule-1（ICAM-1）, interleukin, tumor necrosis factor-α（TNF-α）. Usage of glucocorticoids, anti-VEGF agents, nonsteroidal anti-inflammatory drugs（NSAIDs） and melatonin to inhibit inflammatory process would be a new approach to protect the BRB.This article reviews the current studies about the effects of inflammatory reaction and inflammatory factor in the pathogenesis of hypoxic-ischemic BRB damage, mechanism of suppressing inflammatory response and anti-inflammatory factor in the treatment of hypoxic-ischemic BRB damage.